ArticleContrast media & molecular imaging2017
Gallium-68 Labeled Iron Oxide Nanoparticles Coated with 2,3-Dicarboxypropane-1,1-diphosphonic Acid as a Potential PET/MR Imaging Agent: A Proof-of-Concept Study.
Article in Contrast media & molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Magnetically responsive electrospun fibers as programmable bioactive scaffolds: From formulation design to magnetically triggered therapy and regeneration.Bioactive materials · 2027Review
- The Development and Challenges of PET/MRI Dual-Modality Imaging Probes-An Update.Journal of magnetic resonance imaging : JMRI · 2025Review
- Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.Future oncology (London, England) · 2025Review
- The use of PET/MRI in radiotherapy.Insights into imaging · 2024Review
- Gamma-Camera Direct Imaging of the Plasma and On/Intra Cellular Distribution of theMaterials (Basel, Switzerland) · 2024Article
- Preparation and PET/CT imaging of implant directedJournal of nanobiotechnology · 2023Article
- Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI.Nanomaterials (Basel, Switzerland) · 2023Review
- A review: hemocompatibility of magnetic nanoparticles and their regenerative medicine, cancer therapy, drug delivery, and bioimaging applications.Frontiers in chemistry · 2023Review
- Preclinical PET and MR Evaluation ofNanomaterials (Basel, Switzerland) · 2022Article
- Methods for Radiolabelling Nanoparticles: PET Use (Part 2).Biomolecules · 2022Review
- Article
- Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled withNanomaterials (Basel, Switzerland) · 2022Article
- Synthesis and In Vitro Evaluation of Gold Nanoparticles Functionalized with Thiol Ligands for Robust Radiolabeling withNanomaterials (Basel, Switzerland) · 2021Article
- Chelator-Free/Chelator-Mediated Radiolabeling of Colloidally Stabilized Iron Oxide Nanoparticles for Biomedical Imaging.Nanomaterials (Basel, Switzerland) · 2021Article
- Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles.Scientific reports · 2021Article
- Magnetically Driven Micro and Nanorobots.Chemical reviews · 2021Article
- Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy.Nanomaterials (Basel, Switzerland) · 2018Review
- A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis.Frontiers in chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to develop a dual-modality PET/MR imaging probe by radiolabeling iron oxide magnetic nanoparticles (IONPs), surface functionalized with water soluble stabilizer 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD), with the positron emitter Gallium-68. Magnetite nanoparticles (Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.